.jetcityimage/iStock Content via Getty Images Morgan Stanley has actually picked Eli Lilly (NYSE: LLY) as its leading biopharma choice for 2025 and also measured yet another nine labels in the space as over weight. The assets bank stated in a keep in mind that it continues to strongly believe “diabesity is actually readied to end up being.